Filtered By:
Specialty: Hematology
Cancer: Acute Leukemia
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 27 results found since Jan 2013.
Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)
Conclusions: The selinexor/HiDAC/Mito regimen is feasible and tolerable at selinexor doses up to 80mg/day or ~50 mg/m2/day twice weekly. This regimen yields an ORR of 64% based on currently available data. We had previously reported molecular correlatives demonstrating the effect of selinexor. The recommended phase 2 dose is 80mg of selinexor.Figure.DisclosuresLarson: Ariad/Takeda: Consultancy, Research Funding; BristolMyers Squibb: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding. Odenike: Agios: Research Funding; Astex: Research Funding; Dava Oncology: Consulta...
Source: Blood - November 21, 2018 Category: Hematology Authors: Wang, A., Weiner, H., Larson, R. A., Odenike, O., Artz, A. S., Bishop, M. R., Godley, L., Thirman, M., Kosuri, S., Churpek, J., Curran, E. K., Pettit, K., Stock, W., Liu, H. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Source Type: research
A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States
There is limited information on the comorbidities and complications in elderly AML patients. In a sample of 3,911 AML patients ( ≥ 65 years) identified from the SEER-Medicare database, AML patients had more comorbidities, higher rates of complications, and a higher risk of developing cardiovascular disease, type 2 diabetes mellitus, and stroke compared to matched non-cancer controls.
Source: Clinical Lymphoma, Myeloma and Leukemia - April 29, 2019 Category: Hematology Authors: Neil Dhopeshwarkar, Shahed Iqbal, Xuehong Wang, Maribel Salas Tags: Original Study Source Type: research
Severe, Fatal Methotrexate-related Neurotoxicity in 2 Adolescent Patients With ALL
Neurotoxicity is a well-documented adverse effect of methotrexate in the treatment of pediatric cancers. The spectrum of symptoms is broad, can include stroke-like episodes and seizures, and classically resolves within days. The majority of patients tolerate subsequent doses without recurrence of symptoms. The population of patients who experience persistent and irreversible neurologic symptoms is poorly described, with the existing literature suggestive of a relationship with radiation therapy. The authors present a case series of 2 patients with pre-B-cell acute lymphoblastic leukemia who developed severe and ultimately ...
Source: Journal of Pediatric Hematology Oncology - October 23, 2020 Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
Hemorrhagic stroke due to leukostasis in pediatric mixed-phenotype acute leukemia
Blood Res. 2021 May 14. doi: 10.5045/br.2021.2021004. Online ahead of print.NO ABSTRACTPMID:33986185 | DOI:10.5045/br.2021.2021004
Source: Blood Research - May 14, 2021 Category: Hematology Authors: Shunsuke Yamamoto Yuhki Koga Kenichi Tetsuhara Noriyuki Kaku Hiroaki Ono Satoshi O Suzuki Toru Iwaki Shouichi Ohga Source Type: research
CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study
Context: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF risk remain unknown. Objective: To describe TTNT and TTD for CLL/SLL patients who initiated a first-line (1L) or second-or-later-line (2L+) therapy with ibrutinib or other regimens, in all patients and for subsets of patients with high baseline risk of AF/AF-related events.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 21, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Qing Huang, Sumeet Panjabi, Annalise Hilts, Stephanie Lu, Marie-H élène Lafeuille, Patrick Lefebvre, Michael Choi Tags: Acute Lymphoblastic Leukemia Source Type: research
